TrialCancer immunology, immunotherapy : CII2021

SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2.

Michael Mark et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.